Literature DB >> 20842582

Parkinson's psychosis.

Laura B Zahodne1, Hubert H Fernandez.   

Abstract

OPINION STATEMENT: Psychosis is a leading reason for nursing home placement of patients with Parkinson's disease (PD). It may also be the single greatest stressor for caregivers of PD patients, it is generally persistent, and its presence markedly increases the risk of mortality. For these reasons, it is essential to recognize and appropriately treat psychosis in PD. Treatment of psychotic symptoms should be initiated after potential medical and environmental causes of delirium (eg, infection) have been eliminated or addressed. Initial pharmacologic changes should include limiting the patient's anti-PD medications to those that are necessary to preserve motor function (ie, eliminating adjunctive agents). Should that fail, an atypical antipsychotic agent is the treatment of choice. Clozapine is presently the gold standard, and quetiapine represents another option because of its ease of use and good tolerability profile. Emerging treatment options include the use of acetylcholinesterase inhibitors, antidepressants, and cognitive behavioral therapy. This article reviews what is currently known about treatment strategies in PD psychosis.

Entities:  

Year:  2010        PMID: 20842582      PMCID: PMC3045857          DOI: 10.1007/s11940-010-0072-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  69 in total

1.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

2.  Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial.

Authors:  E Mohr; T Mendis; K Hildebrand; P P De Deyn
Journal:  Mov Disord       Date:  2000-11       Impact factor: 10.338

3.  Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.

Authors:  D Aarsland; K Laake; J P Larsen; C Janvin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

4.  Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.

Authors:  R Bullock; A Cameron
Journal:  Curr Med Res Opin       Date:  2002       Impact factor: 2.580

5.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

6.  Aripiprazole and Parkinson's disease psychosis.

Authors:  Carlos Schönfeldt-Lecuona; Bernhard J Connemann
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

7.  Donepezil in the treatment of hallucinations and delusions in Parkinson's disease.

Authors:  G Fabbrini; P Barbanti; C Aurilia; C Pauletti; G L Lenzi; G Meco
Journal:  Neurol Sci       Date:  2002-04       Impact factor: 3.307

8.  Olanzapine treatment for dopaminergic-induced hallucinations.

Authors:  William G Ondo; Joel K Levy; Kevin Dat Vuong; Christine Hunter; Joseph Jankovic
Journal:  Mov Disord       Date:  2002-09       Impact factor: 10.338

9.  Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study.

Authors:  Hubert H Fernandez; Michael S Okun; Ramon L Rodriguez; Irene A Malaty; Janet Romrell; Anqi Sun; Samuel S Wu; Sandeep Pillarisetty; Anand Nyathappa; Stephan Eisenschenk
Journal:  Int J Neurosci       Date:  2009       Impact factor: 2.292

10.  Pharmacology of hallucinations induced by long-term drug therapy.

Authors:  C G Goetz; C M Tanner; H L Klawans
Journal:  Am J Psychiatry       Date:  1982-04       Impact factor: 18.112

View more
  2 in total

1.  Further characterisation of psychosis-like behaviours induced by L-DOPA in the MPTP-lesioned marmoset.

Authors:  Cynthia Kwan; Stephen G Nuara; Jim C Gourdon; Philippe Huot
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-05-08       Impact factor: 3.000

2.  Adenosine A(2A) Receptor Antagonists Do Not Disrupt Rodent Prepulse Inhibition: An Improved Side Effect Profile in the Treatment of Parkinson's Disease.

Authors:  Carina J Bleickardt; Abigail L Lashomb; Carrie E Merkel; Robert A Hodgson
Journal:  Parkinsons Dis       Date:  2011-12-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.